A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2010
At a glance
- Drugs Carboplatin; Paclitaxel; Saracatinib
- Indications Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 03 Nov 2009 New trial record